Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.

Biotechnology

Education

Sonoma Biotherapeutics

Jeff Bluestone

Jimmy Chung

Stacey Delaney

Melisa S. Medrano

Taylor Le Donne

Michael Thomas

Claire Crowther

Sabrina Fox-Bosetti

Melita Dvorak-Ewell

Jessica Stitt

Peter Dilaura

Doug Sheehy

Fred Ramsdell

Scientific Research Team

Leadership Team

Clinical Operations Team

Finance and Accounting Team

Legal and Compliance Team

Teams at Sonoma Biotherapeutics

Scientific Research Team

Leadership Team

Clinical Operations Team

Finance and Accounting Team

Legal and Compliance Team